DPP4 and hypertensive disorder: In concomitant anti-diabetic medications, the proportion of patients receiving dipeptidyl peptidase-4 inhibitors (DPP4i) (28.3%) was the highest followed by sodium-glucose co-transporter-2 inhibitors (SGLT2i) (12.9%), alpha-glucosidase inhibitor (AGI) (8.6%), thiazolidinedione (TZD) (3.6%), and glucagon-like peptide-1 (GLP1) agonist (0.6%) (Table 3). The common comorbid conditions included hypertension (64.7%), dyslipidemia (39.1%), followed by neuropathy (14.7%), and coronary artery disease (10.6%) across the study population (Figure 3).